Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

VANCOUVER, BC, January 06, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep. 

Are you an angel?

Public Announcements

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…

Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…

Zero Candida Technologies Announces DTC Eligibility and to Present at OTCQB Venture Virtual Investor Conference on August 7th

VANCOUVER, BC, Aug. 5, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…